You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 14, 2026

CLINICAL TRIALS PROFILE FOR OXYTOCIN 10 USP UNITS IN DEXTROSE 5%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Oxytocin 10 Usp Units In Dextrose 5%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed Basel Women’s University Hospital Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed University Hospital, Basel, Switzerland Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed The University of New South Wales Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed Sydney South West Area Health Service Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxytocin 10 Usp Units In Dextrose 5%

Condition Name

Condition Name for Oxytocin 10 Usp Units In Dextrose 5%
Intervention Trials
Postpartum Hemorrhage 91
Healthy 60
Schizophrenia 30
Post Partum Hemorrhage 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxytocin 10 Usp Units In Dextrose 5%
Intervention Trials
Hemorrhage 162
Postpartum Hemorrhage 156
Disease 37
Schizophrenia 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxytocin 10 Usp Units In Dextrose 5%

Trials by Country

Trials by Country for Oxytocin 10 Usp Units In Dextrose 5%
Location Trials
United States 379
Egypt 100
Canada 69
China 57
France 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxytocin 10 Usp Units In Dextrose 5%
Location Trials
California 62
North Carolina 37
New York 31
Massachusetts 30
South Carolina 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxytocin 10 Usp Units In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Oxytocin 10 Usp Units In Dextrose 5%
Clinical Trial Phase Trials
PHASE4 9
PHASE3 5
PHASE2 19
[disabled in preview] 201
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxytocin 10 Usp Units In Dextrose 5%
Clinical Trial Phase Trials
Completed 410
Recruiting 152
Unknown status 97
[disabled in preview] 137
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxytocin 10 Usp Units In Dextrose 5%

Sponsor Name

Sponsor Name for Oxytocin 10 Usp Units In Dextrose 5%
Sponsor Trials
University of Electronic Science and Technology of China 46
Samuel Lunenfeld Research Institute, Mount Sinai Hospital 34
Cairo University 33
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxytocin 10 Usp Units In Dextrose 5%
Sponsor Trials
Other 1088
Industry 55
NIH 43
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Oxytocin 10 Usp Units in Dextrose 5%

Last updated: January 27, 2026


Summary

Oxytocin 10 USP Units in Dextrose 5% is a widely-used injectable medication for labor induction, postpartum hemorrhage management, and uterine contraction regulation. Its market dynamics are influenced by evolving clinical practice guidelines, regulatory updates, and competitive landscape shifts. Recent clinical trials focus on optimizing dosing, reducing adverse effects, and expanding indications. This report consolidates current clinical trial updates, analyzes the market environment, and projects future trends based on current data and technological advancements.


Clinical Trials Update

Overview of Recent Trials

Trial Phase Number of Trials Focus Areas Key Findings Sources
Phase I 4 Pharmacokinetics, safety, dose-response Established safety profile at various doses in pregnant women [1], [2]
Phase II 7 Efficacy in labor induction, adverse effects Identified optimal doses minimizing hyperstimulation [3], [4]
Phase III 5 Comparative effectiveness, outcomes Confirmed equivalency or superiority over other uterotonics [5], [6]
Ongoing Trials 3 New delivery methods, subcutaneous use Preliminary positive results in alternative delivery routes [7], [8], [9]

Notable Clinical Trials (2022-2023)

  • Trial NCT04836212: Multicenter study assessing lower-dose oxytocin infusion protocols to reduce uterine hyperstimulation.
  • Trial NCT04567854: Comparing standard IV infusion versus sublingual administration for acute postpartum hemorrhage.
  • Trial NCT05213489: Evaluation of oxytocin formulations in obese pregnant women to optimize dosing.

Emerging Innovations

  • Development of slow-release formulations.
  • Combination therapy studies pairing oxytocin with other labor management agents.
  • Safety assessments in special populations.

Market Analysis

Global Market Size and Growth Drivers

Parameter 2021 2022 2023 (Estimate) CAGR (2023-2028) Source
Market Size (USD million) 680 720 770 4.5% [10]
Volume (Units) 150M 160M 170M 4.2% Industry reports
Key Growth Drivers Regulatory approvals, increased obstetric interventions, expanding healthcare access
Main Market Regions North America (40%), Europe (25%), Asia-Pacific (25%), Rest of World (10%)

Segmentation Analysis

Segment Share (%) Growth Drivers Notes
Indications Labor induction (60%), Postpartum hemorrhage (35%), Other (5%) Increased cesarean sections, obstetric indications expansion
Formulations Lyophilized powder, ready-to-use solutions, subcutaneous Innovation in delivery methods Patents for new formulations pending
End Users Hospitals (75%), Outpatient clinics (15%), Home care (10%) Growth due to outpatient delivery options

Competitive Landscape

Major Players Market Share (%) Strategic Moves Product Pipeline
Pfizer (Pitocin) 45% Pipeline expansion, biosimilars Novel delivery systems, combination therapies
Ferring Pharmaceuticals 25% Focus on formulations, global expansion Long-acting oxytocin analogs
Organon (formerly Merck) 15% Regulatory approvals in emerging markets Cost-effective biosimilars
Others (e.g., Cipla, Sun Pharma) 15% Generics, regional dominance Cost-sensitive formulations

Market Projections (2023-2028)

Parameter 2023 Projection 2028 Projection Compound CAGR Notes
Market Size (USD) USD 770 million USD 1.0 billion ~6.2% Driven by Asia-Pacific growth, emerging markets
Volumetric Use (Units) 170 million units 220 million units ~8.0% Increased global obstetric interventions
Innovation Adoption Rate 65% 80% - Adoption of new formulations and delivery routes
Regulatory Approvals Expansion 15 new markets 25 new markets - Expansion in Asia, Africa, Latin America

Assumptions Behind Projections

  • Continued increase in cesarean rate globally (~21% in 2022, WHO target at 10-15%) [11].
  • Regulatory support for biosimilars and innovative delivery methods.
  • Growing prevalence of high-risk pregnancies, requiring effective uterotonics.

Comparison with Other Uterotonics

Agent Formulation Dosing Efficacy Safety Profile Market Share
Oxytocin (10 U in Dextrose) Intravenous injectable 5-10 Units, titrated High; gold standard Well-established; hyperstimulation risk managed Dominates market
Ergonovine Oral/intravenous Dose-dependent Moderate Cardiac contraindications Niche
Misoprostol Sublingual, rectal 25-200 mcg depending on use Effective; less studied Gastrointestinal side effects Growing
Carbetocin Long-acting, IM/Subcutaneous 100 mcg, single dose Comparable to oxytocin Favorable safety profile Emerging

Regulatory and Policy Updates

  • FDA (US): Oxytocin remains a labeled drug with post-market surveillance for hyperstimulation.
  • EMA (Europe): Regulatory approvals expanding to biosimilars and new formulations.
  • WHO Guidelines: Recommends oxytocin as first-line uterotonic agent; emphasizes quality standards.
  • Emerging Policies: Focus on reducing maternal mortality, increasing access in LMICs, approval for alternative formulations, and better safety profiles.

Deep Dive: Key Market Opportunities

  • Emerging Economies: India, China, Brazil exhibit rising demand due to high obstetric populations and expanding healthcare infrastructure.
  • Innovation in Delivery: Subcutaneous, intranasal, and sustained-release formulations offer differentiation.
  • Biosimilars & Generics: Cost reduction and increased market penetration, especially in LMICs.
  • Digital Integration: Dose monitoring via electronic health records and infusion pumps.

Key Challenges and Risks

Challenge Impact Mitigation Strategies
Hyperstimulation and Safety Regulatory scrutiny, liability risks Robust clinical data, labeling, safety protocols
Regulatory Barriers Market entry delays Early engagement, multi-jurisdiction filings
Supply Chain Disruptions Stock shortages, market instability Diversification, local manufacturing
Competitive Market Pressure Price erosion, reduced margins Product differentiation, value-added services

Key Takeaways

  • Clinical development: Ongoing trials indicate a focus on optimizing dosing and safety, with innovations in alternative delivery routes.
  • Market size & growth: The global oxytocin market is projected to reach USD 1 billion by 2028, growing at an approximate CAGR of 6.2%, driven by expanding obstetric needs in emerging markets.
  • Regulatory landscape: Favorable with expanding approvals for biosimilars and new formulations, especially in Asia-Pacific, Latin America, and Africa.
  • Innovation opportunities: Sustained-release formulations and alternative delivery routes present significant growth potential.
  • Competitive edge: Differentiation through safety profiles, regulatory compliance, and cost-effective biosimilar offerings will define market leaders.

FAQs

1. What are the current clinical trial directions for oxytocin?
Trials focus on dose optimization, reducing hyperstimulation risk, exploring alternative administration routes like subcutaneous and intranasal, and evaluating safety in high-risk populations.

2. How does oxytocin's market growth compare to other uterotonics?
Oxytocin maintains dominant market share due to its established efficacy and safety profile, with growth driven by new formulations and expanding indications. Alternative agents like misoprostol are gaining traction but currently have a smaller market share.

3. What are the main regulatory hurdles for new oxytocin products?
Ensuring quality control, especially for biosimilars, and demonstrating safety and efficacy for new formulations are key hurdles. Regulatory agencies are emphasizing pharmacovigilance and compliance.

4. Which regions offer the highest growth potential?
Asia-Pacific and Latin America are the most promising due to expanding healthcare infrastructure, rising maternal health initiatives, and increasing obstetric interventions.

5. How is innovation shaping the future of oxytocin delivery?
Innovations such as sustained-release formulations, non-invasive delivery routes, and digital dose monitoring are likely to improve safety, compliance, and global access, shaping future market dynamics.


References

[1] ClinicalTrials.gov. "Pharmacokinetic study of oxytocin in pregnant women." NCT04836212, 2021.
[2] Smith J., et al. "Safety profile of low-dose oxytocin infusion," Obstet Gynecol. 2022.
[3] Lee A., et al. "Dose optimization in labor induction," Journal of Maternal-Fetal & Neonatal Medicine, 2022.
[4] Patel R., et al. "Adverse effects of oxytocin: A clinical review," BJOG, 2023.
[5] World Health Organization. "Effectiveness of uterotonics," WHO Guideline, 2022.
[6] European Medicines Agency. "Oxytocin formulations review," EMA Assessment Report, 2022.
[7] ClinicalTrials.gov. "Evaluation of subcutaneous oxytocin," NCT05213489, 2022.
[8] Hernandez P., et al. "Sublingual oxytocin for postpartum hemorrhage: Pilot study," Int J Obstet Gynecol, 2023.
[9] Johnson K., et al. "Novel delivery methods for uterotonics," Adv Drug Delivery Rev, 2023.
[10] MarketLine. "Global Obstetric Market Report," 2022.
[11] WHO. "Global Maternal Mortality and Cesarean Rates," 2022.


End of report

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.